• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

    23.21 -0.67 (-2.81%)
    Streaming Delayed Price Updated: 2:08 PM EDT, Aug 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 265,934
    Open 23.58
    Bid (Size) 23.20 (100)
    Ask (Size) 23.22 (300)
    Prev. Close 23.88
    Today's Range 23.07 - 23.70
    52wk Range 13.18 - 34.29
    Shares Outstanding 9,587,155
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -24.3%
    -24.3%
    1 Month
    +19.0%
    +19.0%
    3 Month
    +33.0%
    +33.0%
    6 Month
    -21.3%
    -21.3%
    1 Year
    +25.1%
    +25.1%

    More News

    Read More
    News headline image
    Viridian Therapeutics to Participate in Upcoming June Investor Conferences
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
    From Viridian Therapeutics, Inc.
    Via Business Wire
    Which stocks are gapping on Tuesday? ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
    Via MarketMinute
    News headline image
    Amgen Reclaims the Lead in Thyroid Eye Disease with Superior Subcutaneous TEPEZZA Data
    Via MarketMinute
    Topics Intellectual Property
    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
    Via MarketMinute
    Topics Intellectual Property
    Which stocks are experiencing notable movement on Monday? ↗
    Via Chartmill
    Here are the top movers in Monday's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Monday's session. ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
    Via The Motley Fool
    News headline image
    Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
    Via The Motley Fool
    News headline image
    Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
    Via The Motley Fool
    News headline image
    What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is Viridian Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?
    Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?
    The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market
    What is the current price of Viridian Therapeutics, Inc. - Common Stock?
    The current price of Viridian Therapeutics, Inc. - Common Stock is 23.21
    When was Viridian Therapeutics, Inc. - Common Stock last traded?
    The last trade of Viridian Therapeutics, Inc. - Common Stock was at 08/28/26 02:08 PM ET
    What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?
    The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 222.52M
    How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?
    Viridian Therapeutics, Inc. - Common Stock has 223M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.